On October 13, 2022 Celdara Medical, LLC reported that the National Cancer Institute (NCI) of the National Institutes of Health (NIH) has awarded a Phase II Small Business Innovation Research (SBIR) Fast-Track grant to fund company’s ongoing development of CM-CX1, a chimeric antigen receptor (CAR) T cell therapy for the treatment of ovarian clear cell and renal cell carcinomas (Press release, Celdara Medical, OCT 13, 2022, View Source [SID1234621985]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Jake Reder, Co-founder and Chief Executive Officer of Celdara Medical, remarked, "We’re very grateful to the NCI for their continued support of this program. As the field begins to see the potential of CAR-T in solid tumors realized, the fundamental importance of target selection comes once again into focus. We’re working hard to bring CM-CX1 to the clinical for the benefit of patients with renal cell or ovarian clear cell carcinomas, or indeed for any patient whose tumor expresses CM-CX1’s target."
"I have been working closely with our industry and academic partners to identify ideal targets for cellular therapies and we have created something unique with CM-CX1", said Dr. Joana Murad Mabaera, Executive Director of Research at Celdara Medical and lead Principal Investigator on the study. "We have made significant progress in Phase I towards the preclinical development of CM-CX1. The Phase II funding will enable the submission of our Investigational New Drug (IND) application to bring CM-CX1 to clinic. With CM-CX1, we have an exciting opportunity to translate our promising research and make this therapeutic option accessible to patients of ovarian and renal carcinomas."
Research reported in this press release is supported by the National Cancer Institute of the National Institutes of Health under award number R44CA265424-02. The content is solely the responsibility of Celdara Medical and does not necessarily represent the official views of the National Institutes of Health.